VEGFA and atherosclerosis: This profound alteration in endothelial function predisposes to atherosclerosis, and indeed, cases of progression of CAD and plaque rupture have been reported for sorafenib and sunitinib, respectively.75, 76 In in vivo experiments, pan-VEGF inhibition markedly accelerated preexisting atherosclerosis yet without an increase in features of plaque vulnerability (Supplemental Figure 3).74